J&J, Pfizer Halt Development of Alzheimer’s Drug
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
The companies both noted the drug, bapineuzumab, did not improve the condition of Alzheimer’s patients compared to a placebo.
Johnson & Johnson will take a $300 million to $400 million charge in the third quarter.
Shares of Pfizer are down 2.51% in after-hours trading. Shares of Johnson & Johnson are up 0.21%.
Samuel Weigley
Contact [email protected] for any questions or corrections.


